<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 3.4d -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: XBRL Optimizer.xfr; Date: 2013/05/14T21:15:40 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2012-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2012-01-31" xmlns:us-roles="http://fasb.org/us-roles/2012-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2012-01-31" xmlns:OPRX="http://OPRX/20130331">
    <link:schemaRef xlink:href="oprx-20130331.xsd" xlink:type="simple" />
    <xbrli:context id="From2013-01-01to2013-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2010-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2010-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2008-04-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2008-04-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2010-04-26">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2010-04-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-01-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-01-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-07-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-07-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2008-01-01to2008-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2008-01-01</xbrli:startDate>
        <xbrli:endDate>2008-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2010-05-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2010-05-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2010-11-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2010-11-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-03-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-03-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-09-21">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-09-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2010-01-01to2010-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2010-01-01</xbrli:startDate>
        <xbrli:endDate>2010-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-02-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-05-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-11-21">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-11-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-10-01to2011-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-10-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-10-01to2012-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-10-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-12-01to2014-12-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-12-01</xbrli:startDate>
        <xbrli:endDate>2014-12-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-12-02to2016-12-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-12-02</xbrli:startDate>
        <xbrli:endDate>2016-12-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-01-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001448431</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-01-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Percent">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <dei:EntityRegistrantName contextRef="From2013-01-01to2013-03-31">OptimizeRx Corp</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2013-01-01to2013-03-31">0001448431</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2013-01-01to2013-03-31">10-Q</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2013-01-01to2013-03-31">2013-03-31</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2013-01-01to2013-03-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2013-01-01to2013-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2013-01-01to2013-03-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2013-01-01to2013-03-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2013-01-01to2013-03-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="From2013-01-01to2013-03-31">Smaller Reporting Company</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus contextRef="From2013-01-01to2013-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2013-01-01to2013-03-31">2013</dei:DocumentFiscalYearFocus>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">260394</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">284263</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">660669</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">616798</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">32336</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">68158</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">953399</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">969219</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">19278</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">20685</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">809472</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">793236</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:CapitalizedComputerSoftwareNet contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">354643</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:CapitalizedComputerSoftwareNet contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">387215</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:SecurityDeposit contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">5049</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">5049</us-gaap:SecurityDeposit>
    <us-gaap:OtherAssets contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">1169164</us-gaap:OtherAssets>
    <us-gaap:OtherAssets contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">1185500</us-gaap:OtherAssets>
    <us-gaap:Assets contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">2141841</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">2175404</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">56686</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">54693</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">570000</us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">570000</us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">43750</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">6000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:DeferredRevenue contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">80772</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">49252</us-gaap:DeferredRevenue>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">751208</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">679945</us-gaap:LiabilitiesCurrent>
    <us-gaap:CommonStockValue contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">14232</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">14232</us-gaap:CommonStockValue>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">20058051</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">20058051</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">6164666</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">6164666</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">-24846316</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">-24741490</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">1390633</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">1495459</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">2141841</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">2175404</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:PreferredStockValue contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>
    <us-gaap:SalesRevenueNet contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">669290</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">329403</us-gaap:SalesRevenueNet>
    <us-gaap:Revenues contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">669290</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">329403</us-gaap:Revenues>
    <us-gaap:OperatingExpenses contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">774172</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">630322</us-gaap:OperatingExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">774172</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">630322</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:InterestAndOtherIncome contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">56</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">185</us-gaap:InterestAndOtherIncome>
    <us-gaap:OtherExpenses contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">56</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">185</us-gaap:OtherExpenses>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">-104826</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">-300734</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="From2013-01-01to2013-03-31" unitRef="Shares" decimals="INF">14232196</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="From2012-01-01to2012-03-31" unitRef="Shares" decimals="INF">14192496</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="From2013-01-01to2013-03-31" unitRef="USDPShares" decimals="INF">-0.01</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="From2012-01-01to2012-03-31" unitRef="USDPShares" decimals="INF">-0.02</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:OperatingIncomeLoss contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">-104882</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">-300919</us-gaap:OperatingIncomeLoss>
    <OPRX:LossBeforeProvisionForIncomeTaxes contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">-104826</OPRX:LossBeforeProvisionForIncomeTaxes>
    <OPRX:LossBeforeProvisionForIncomeTaxes contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">-300734</OPRX:LossBeforeProvisionForIncomeTaxes>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DepreciationAndAmortization contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">48111</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">46023</us-gaap:DepreciationAndAmortization>
    <OPRX:StockbasedCompensation contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">0</OPRX:StockbasedCompensation>
    <OPRX:StockbasedCompensation contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">120054</OPRX:StockbasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">-43871</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">355412</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">35822</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">5033</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">1993</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">-159640</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">37750</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">-66700</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">31520</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">-127452</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">1424</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:CapitalizedComputerSoftwareAmortization contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">0</us-gaap:CapitalizedComputerSoftwareAmortization>
    <us-gaap:CapitalizedComputerSoftwareAmortization contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">-32235</us-gaap:CapitalizedComputerSoftwareAmortization>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">-23869</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">-161663</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <OPRX:CashAndCashEquivalentsBeginning contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">284263</OPRX:CashAndCashEquivalentsBeginning>
    <OPRX:CashAndCashEquivalentsBeginning contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">959166</OPRX:CashAndCashEquivalentsBeginning>
    <OPRX:CashAndCashEquivalentsEnding contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">260394</OPRX:CashAndCashEquivalentsEnding>
    <OPRX:CashAndCashEquivalentsEnding contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">797503</OPRX:CashAndCashEquivalentsEnding>
    <us-gaap:NetIncomeLoss contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">-104826</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">-300734</us-gaap:NetIncomeLoss>
    <us-gaap:InterestPaid contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">0</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">0</us-gaap:InterestPaid>
    <us-gaap:IncomeTaxesPaid contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">6499</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">-128004</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <OPRX:PatentRights contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">-30368</OPRX:PatentRights>
    <OPRX:PatentRights contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">0</OPRX:PatentRights>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">-30368</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">-33659</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2013-03-31" unitRef="USDPShares" decimals="INF">.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2012-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2013-03-31" unitRef="USDPShares" decimals="INF">.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2012-12-31" unitRef="USDPShares" decimals="INF">.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2013-03-31" unitRef="Shares" decimals="INF">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2013-03-31" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2013-03-31" unitRef="Shares" decimals="INF">14232496</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">14232496</us-gaap:CommonStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2013-03-31" unitRef="Shares" decimals="INF">65</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">65</us-gaap:PreferredStockSharesIssued>
    <us-gaap:NatureOfOperations contextRef="From2013-01-01to2013-03-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Optimizer Systems, LLC was formed in the&#13;State of Michigan on January 31, 2006. It then became a corporation in the State of Michigan on October 22, 2007 and changed its&#13;name to OptimizeRx Corporation. On April 14, 2008, RFID, Ltd., a Colorado corporation, consummated a reverse merger by entering&#13;into a share exchange agreement with the stockholders of OptimizeRx Corporation, pursuant to which the stockholders of OptimizeRx&#13;Corporation exchanged all of the issued and outstanding capital stock of OptimizeRx Corporation for 1,256,958 shares of common&#13;stock of RFID, Ltd., representing 100% of the outstanding capital stock of RFID, Ltd. As of April&amp;#160;30, 2008, RFID&amp;#146;s officers&#13;and directors resigned their positions and RFID changed its business to OptimizeRx&amp;#146;s business. On April&amp;#160;15, 2008, RFID,&#13;Ltd.&amp;#146;s corporate name was changed to OptimizeRx Corporation. On September&amp;#160;4, 2008, a migratory merger was completed,&#13;thereby changing the state of incorporation from Colorado to Nevada, resulting in the current corporate structure, in which OptimizeRx&#13;Corporation, a Nevada corporation, is the parent corporation, and OptimizeRx Corporation, a Michigan corporation, is a wholly-owned&#13;subsidiary (together, "OptimizeRx" and "the Company").&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The wholly-owned subsidiary, OptimizeRx&#13;Corporation, is a technology solutions company targeting the health care industry. Their objective is to bring better access to&#13;better care through connecting patients, physicians and pharmaceutical manufacturers through technology. Once defined as a marketing&#13;and advertising company through its consumer website, OptimizeRx is maturing as a technology solutions provider as it launched&#13;its direct to physician solution, SampleMD. SampleMD allows physicians to search, print and send available sample trial vouchers&#13;and/or co-pay coupons on behalf of their patients. The SampleMD solution can either sit on the doctor&amp;#146;s desktop or can be&#13;integrated into the ePrescribing or Electronic Medical Records applications. OptimizeRx solutions provide pharmaceutical manufacturers&#13;either a direct to consumer and/or direct to physician channels for communicating and promoting their products. It provides health&#13;care providers a means to provide sampling and coupons without having to physically store samples on site, and it provides better&#13;access and affordability to the patients.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2013-01-01to2013-03-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;u&gt;Basis of Presentation&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;&lt;font style="letter-spacing: 0pt"&gt;The&#13;accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally&#13;accepted in the United States of America and the rules of the Securities and Exchange Commission (&amp;#147;SEC&amp;#148;), and should&#13;be read in conjunction with the audited financial statements and notes thereto contained in the Company&amp;#146;s Form 10-K filed&#13;with the SEC as of and for the year ended December 31, 2012. In the opinion of management, all adjustments necessary for the financial&#13;statements to be not misleading for the interim periods presented have been reflected herein. The results of operations for interim&#13;periods are not necessarily indicative of the results to be expected for the full year.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;u&gt;Accounting Basis&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company uses the accrual basis of accounting&#13;and accounting principles generally accepted in the United States of America (&amp;#147;GAAP&amp;#148; accounting). The Company has adopted&#13;a December 31 fiscal year end.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;&lt;font style="font-weight: normal"&gt;&lt;u&gt;Principles&#13;of Consolidation&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;The financial statements&#13;reflect the consolidated results of OptimizeRx Corporation (a Nevada corporation) and its wholly owned subsidiary OptimizeRx Corporation&#13;(a Michigan corporation). All material inter-company transactions have been eliminated in the consolidation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: center"&gt;&lt;b&gt;OPTIMIZERx CORPORATION&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;&lt;b&gt;NOTES&#13;TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;&lt;b&gt;MARCH&amp;#160;31,&#13;2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: left"&gt;&lt;font style="letter-spacing: 0pt"&gt;NOTE&#13;2 &amp;#150; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;&lt;font style="font-weight: normal"&gt;&lt;u&gt;Cash&#13;and Cash Equivalents&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;For purposes of&#13;the accompanying financial statements, the Company considers all highly liquid instruments with an initial maturity of three months&#13;or less to be cash equivalents.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;u&gt;Fair Value of Financial Instruments&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;The fair value&#13;of cash, accounts receivable, prepaid expenses, patent rights, web development costs, accounts payable, accounts payable &amp;#150;&#13;related party, accrued expenses and deferred revenue approximates the carrying amount of these financial instruments due to their&#13;short-term nature. The fair value of long-term debt, which approximates its carrying value, is based on current rates at which&#13;the Company could borrow funds with similar remaining maturities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;u&gt;Accounts Receivable and Allowance for&#13;Doubtful Accounts&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accounts receivable are reported at realizable&#13;value, net of allowances for doubtful accounts, which is estimated and recorded in the period the related revenue is recorded.&#13;The Company has a standardized approach to estimate and review the collectability of its receivables based on a number of factors,&#13;including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of&#13;the estimation process related to allowances for doubtful accounts. In addition, the Company regularly assesses the state of its&#13;billing operations in order to identify issues, which may impact the collectability of these receivables or reserve estimates.&#13;Bad debt expense was $0 for the three months ended March 31, 2013 and 2012, respectively. The allowance for doubtful accounts was&#13;$0 as of March 31, 2013 and December 31, 2012, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;u&gt;Property and Equipment&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;The capital assets&#13;are being depreciated over their estimated useful lives, three to seven years using the straight-line method of depreciation for&#13;book purposes.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;u&gt;Revenue Recognition&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;All revenue is recognized when it is earned.&#13;Revenues are generated either through the Company&amp;#146;s website activities, in which we earn revenue from advertising and lead&#13;generation activities, or from our SampleMD activities, which include offering setup within the systems and our offers, coupons,&#13;and vouchers that enable our customers to save money on medical products and services. The Company&amp;#146;s processes are monitored&#13;by third parties who collect revenues from clients on a per activity basis and report and forward the revenue to the Company&amp;#146;s&#13;account.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;u&gt;Research and Development&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;The Company&amp;#146;s&#13;key members are part of a continual research development team and monitor new technologies, trends, services and partnerships that&#13;can provide the Company with additional services, value to healthcare and pharmaceutical industries and to the patients it serves.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;The Company seeks&#13;to educate team members through understanding of all market dynamics that have the potential to affect the business both short&#13;term and longer term. The primary goal is to help patients better afford and access the medicines their doctor prescribes, as well&#13;as other healthcare products and services they need. Based on this, the Company continually seeks better ways to meet this mission&#13;through technology, better user experiences and new ways to engage industries to provide new support for patients needing their&#13;products. The Company is always seeking new services and solutions to offer. At this time, the three current platforms provide&#13;robust opportunities and growth during the next five years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: center"&gt;&lt;b&gt;OPTIMIZERx CORPORATION&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;&lt;b&gt;NOTES&#13;TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;&lt;b&gt;MARCH&amp;#160;31,&#13;2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: left"&gt;&lt;font style="letter-spacing: 0pt"&gt;NOTE&#13;2 &amp;#150; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;u&gt;Income Taxes&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Income taxes are computed using the asset&#13;and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on&#13;the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted&#13;tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence,&#13;are not expected to be realized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;u&gt;Concentration of Credit Risks&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;The Company maintains&#13;its cash and cash equivalents in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not&#13;experienced any losses in such accounts; however, amounts in excess of the federally insured limit may be at risk if the bank experiences&#13;financial difficulties.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;u&gt;Use of Estimates&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;The preparation&#13;of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions&#13;that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of&#13;revenues and expenses during the reporting period. Estimates and assumptions have been made in determining the depreciable lives&#13;of such assets and the allowance for doubtful accounts receivable. Actual results could differ from these estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;u&gt;Earnings Per Common and Common Equivalent&#13;Share&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;The computation&#13;of basic earnings per common share is computed using the weighted average number of common shares outstanding during the year.&#13;The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the year&#13;plus common stock equivalents which would arise from the exercise of warrants outstanding using the treasury stock method and the&#13;average market price per share during the year. Options, warrants and convertible preferred stock which are common stock equivalents&#13;are not included in the diluted earnings per share calculation for March 31, 2013 and 2012, respectively, since their effect is&#13;anti-dilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;u&gt;Impairment of Long-Lived Assets&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;The Company continually&#13;monitors events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be recoverable.&#13;When such events or changes in circumstances are present, the Company assesses the recoverability of long-lived assets by determining&#13;whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the&#13;future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess&#13;of the carrying amount over the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount&#13;or the fair value less costs to sell.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;u&gt;Recently Issued Accounting Guidance&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;The Company does&#13;not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company&amp;#146;s results&#13;of operations, financial position or cash flow.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2013-01-01to2013-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;u&gt;Basis of Presentation&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;&lt;font style="letter-spacing: 0pt"&gt;The&#13;accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally&#13;accepted in the United States of America and the rules of the Securities and Exchange Commission (&amp;#147;SEC&amp;#148;), and should&#13;be read in conjunction with the audited financial statements and notes thereto contained in the Company&amp;#146;s Form 10-K filed&#13;with the SEC as of and for the year ended December 31, 2012. In the opinion of management, all adjustments necessary for the financial&#13;statements to be not misleading for the interim periods presented have been reflected herein. The results of operations for interim&#13;periods are not necessarily indicative of the results to be expected for the full year.&lt;/font&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <OPRX:SignificantAccountingPolicyPoliciesTextBlock contextRef="From2013-01-01to2013-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;u&gt;Accounting Basis&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company uses the accrual basis of accounting&#13;and accounting principles generally accepted in the United States of America (&amp;#147;GAAP&amp;#148; accounting). The Company has adopted&#13;a December 31 fiscal year end.&lt;/p&gt;</OPRX:SignificantAccountingPolicyPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2013-01-01to2013-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;&lt;font style="font-weight: normal"&gt;&lt;u&gt;Principles&#13;of Consolidation&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;The financial statements&#13;reflect the consolidated results of OptimizeRx Corporation (a Nevada corporation) and its wholly owned subsidiary OptimizeRx Corporation&#13;(a Michigan corporation). All material inter-company transactions have been eliminated in the consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2013-01-01to2013-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;&lt;font style="font-weight: normal"&gt;&lt;u&gt;Cash&#13;and Cash Equivalents&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;For purposes of&#13;the accompanying financial statements, the Company considers all highly liquid instruments with an initial maturity of three months&#13;or less to be cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2013-01-01to2013-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;u&gt;Fair Value of Financial Instruments&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;The fair value&#13;of cash, accounts receivable, prepaid expenses, patent rights, web development costs, accounts payable, accounts payable &amp;#150;&#13;related party, accrued expenses and deferred revenue approximates the carrying amount of these financial instruments due to their&#13;short-term nature. The fair value of long-term debt, which approximates its carrying value, is based on current rates at which&#13;the Company could borrow funds with similar remaining maturities.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PremiumsReceivableAllowanceForDoubtfulAccountsEstimationMethodologyPolicy contextRef="From2013-01-01to2013-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;u&gt;Accounts Receivable and Allowance for&#13;Doubtful Accounts&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accounts receivable are reported at realizable&#13;value, net of allowances for doubtful accounts, which is estimated and recorded in the period the related revenue is recorded.&#13;The Company has a standardized approach to estimate and review the collectability of its receivables based on a number of factors,&#13;including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of&#13;the estimation process related to allowances for doubtful accounts. In addition, the Company regularly assesses the state of its&#13;billing operations in order to identify issues, which may impact the collectability of these receivables or reserve estimates.&#13;Bad debt expense was $0 for the three months ended March 31, 2013 and 2012, respectively. The allowance for doubtful accounts was&#13;$0 as of March 31, 2013 and December 31, 2012, respectively.&lt;/p&gt;</us-gaap:PremiumsReceivableAllowanceForDoubtfulAccountsEstimationMethodologyPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2013-01-01to2013-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;u&gt;Property and Equipment&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;The capital assets&#13;are being depreciated over their estimated useful lives, three to seven years using the straight-line method of depreciation for&#13;book purposes.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2013-01-01to2013-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;u&gt;Revenue Recognition&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;All revenue is recognized when it is earned.&#13;Revenues are generated either through the Company&amp;#146;s website activities, in which we earn revenue from advertising and lead&#13;generation activities, or from our SampleMD activities, which include offering setup within the systems and our offers, coupons,&#13;and vouchers that enable our customers to save money on medical products and services. The Company&amp;#146;s processes are monitored&#13;by third parties who collect revenues from clients on a per activity basis and report and forward the revenue to the Company&amp;#146;s&#13;account.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="From2013-01-01to2013-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;u&gt;Research and Development&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;The Company&amp;#146;s&#13;key members are part of a continual research development team and monitor new technologies, trends, services and partnerships that&#13;can provide the Company with additional services, value to healthcare and pharmaceutical industries and to the patients it serves.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;The Company seeks&#13;to educate team members through understanding of all market dynamics that have the potential to affect the business both short&#13;term and longer term. The primary goal is to help patients better afford and access the medicines their doctor prescribes, as well&#13;as other healthcare products and services they need. Based on this, the Company continually seeks better ways to meet this mission&#13;through technology, better user experiences and new ways to engage industries to provide new support for patients needing their&#13;products. The Company is always seeking new services and solutions to offer. At this time, the three current platforms provide&#13;robust opportunities and growth during the next five years.&lt;/p&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2013-01-01to2013-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;u&gt;Income Taxes&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Income taxes are computed using the asset&#13;and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on&#13;the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted&#13;tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence,&#13;are not expected to be realized.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2013-01-01to2013-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;u&gt;Concentration of Credit Risks&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;The Company maintains&#13;its cash and cash equivalents in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not&#13;experienced any losses in such accounts; however, amounts in excess of the federally insured limit may be at risk if the bank experiences&#13;financial difficulties.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:UseOfEstimates contextRef="From2013-01-01to2013-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;u&gt;Use of Estimates&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;The preparation&#13;of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions&#13;that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of&#13;revenues and expenses during the reporting period. Estimates and assumptions have been made in determining the depreciable lives&#13;of such assets and the allowance for doubtful accounts receivable. Actual results could differ from these estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2013-01-01to2013-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;u&gt;Earnings Per Common and Common Equivalent&#13;Share&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;The computation&#13;of basic earnings per common share is computed using the weighted average number of common shares outstanding during the year.&#13;The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the year&#13;plus common stock equivalents which would arise from the exercise of warrants outstanding using the treasury stock method and the&#13;average market price per share during the year. Options, warrants and convertible preferred stock which are common stock equivalents&#13;are not included in the diluted earnings per share calculation for March 31, 2013 and 2012, respectively, since their effect is&#13;anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2013-01-01to2013-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;u&gt;Impairment of Long-Lived Assets&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;The Company continually&#13;monitors events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be recoverable.&#13;When such events or changes in circumstances are present, the Company assesses the recoverability of long-lived assets by determining&#13;whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the&#13;future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess&#13;of the carrying amount over the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount&#13;or the fair value less costs to sell.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2013-01-01to2013-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;u&gt;Recently Issued Accounting Guidance&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;The Company does&#13;not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company&amp;#146;s results&#13;of operations, financial position or cash flow.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <OPRX:PrepaidExpensesTextBlock contextRef="From2013-01-01to2013-03-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;Prepaid expenses&#13;consisted of the following as of March&amp;#160;31, 2013 and December&amp;#160;31, 2012:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="border-collapse: collapse; font-size: 10pt; width: 65%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-left: 5.4pt; width: 54%"&gt;Insurance&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 20%"&gt;5,617&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 20%"&gt;6,437&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Rent&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5,049&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5,049&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Consulting&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;21,670&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;31,672&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 5.4pt"&gt;Legal&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;25,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 5.4pt"&gt;Total prepaid expenses&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;32,336&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;68,158&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</OPRX:PrepaidExpensesTextBlock>
    <OPRX:ScheduleOfPrepaidExpensesTableTextBlock contextRef="From2013-01-01to2013-03-31">&lt;table cellspacing="0" cellpadding="0" align="center" style="border-collapse: collapse; font-size: 10pt; width: 65%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-left: 5.4pt; width: 54%"&gt;Insurance&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 20%"&gt;5,617&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 20%"&gt;6,437&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Rent&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5,049&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5,049&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Consulting&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;21,670&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;31,672&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 5.4pt"&gt;Legal&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;25,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 5.4pt"&gt;Total prepaid expenses&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;32,336&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;68,158&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</OPRX:ScheduleOfPrepaidExpensesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2013-01-01to2013-03-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company owned equipment recorded at&#13;cost which consisted of the following as of March&amp;#160;31, 2013 and December&amp;#160;31, 2012:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="border-collapse: collapse; font-size: 10pt; width: 65%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt; width: 54%"&gt;Computer equipment&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 20%"&gt;22,360&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 20%"&gt;22,360&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left; padding-left: 5.4pt"&gt;Furniture and fixtures&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;11,088&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;11,088&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Subtotal&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;33,448&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;33,448&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left; padding-left: 5.4pt"&gt;Accumulated depreciation&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(14,170&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(12,763&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Property and equipment, net&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;19,278&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;20,685&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Depreciation expense was $1,407 and $1,300&#13;for the three months ended March&amp;#160;31, 2013 and 2012, respectively.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <OPRX:ScheduleOfPropertyEquipmentTextBlock contextRef="From2013-01-01to2013-03-31">&lt;table cellspacing="0" cellpadding="0" align="center" style="border-collapse: collapse; font-size: 10pt; width: 65%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt; width: 54%"&gt;Computer equipment&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 20%"&gt;22,360&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 20%"&gt;22,360&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left; padding-left: 5.4pt"&gt;Furniture and fixtures&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;11,088&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;11,088&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Subtotal&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;33,448&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;33,448&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left; padding-left: 5.4pt"&gt;Accumulated depreciation&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(14,170&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(12,763&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Property and equipment, net&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;19,278&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;20,685&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</OPRX:ScheduleOfPropertyEquipmentTextBlock>
    <us-gaap:Depreciation contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">1407</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">1300</us-gaap:Depreciation>
    <OPRX:WebsiteDevelopmentTextBlock contextRef="From2013-01-01to2013-03-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has capitalized costs in developing&#13;their website and web-based products, which consisted of the following as of March&amp;#160;31, 2013 and December&amp;#160;31, 2012:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="border-collapse: collapse; font-size: 10pt; width: 65%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt; width: 54%"&gt;OptimizeRx web development&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 20%"&gt;154,133&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 20%"&gt;154,133&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left; padding-left: 5.4pt"&gt;SampleMD web development&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;602,517&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;602,517&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Subtotal, web development costs&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;756,650&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;756,650&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Accumulated amortization&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(342,924&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(310,352&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 5.4pt"&gt;Impairment&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(59,083&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(59,083&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Web development costs, net&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;354,643&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;387,215&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Amortization is recorded using the straight-line&#13;method over a period of five years. The Company determined that the original OptimizeRx website was no longer useful so the remaining&#13;unamortized balance of $59,083 was impaired as of December&amp;#160;31, 2010. Amortization expense for the web development costs was&#13;$32,572 and $31,047 for the three months ended March&amp;#160;31, 2013 and 2012, respectively.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</OPRX:WebsiteDevelopmentTextBlock>
    <OPRX:ScheduleOfWebsiteDevelopmentCostsTableTextBlock contextRef="From2013-01-01to2013-03-31">&lt;table cellspacing="0" cellpadding="0" align="center" style="border-collapse: collapse; font-size: 10pt; width: 65%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt; width: 54%"&gt;OptimizeRx web development&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 20%"&gt;154,133&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 20%"&gt;154,133&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left; padding-left: 5.4pt"&gt;SampleMD web development&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;602,517&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;602,517&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Subtotal, web development costs&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;756,650&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;756,650&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Accumulated amortization&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(342,924&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(310,352&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 5.4pt"&gt;Impairment&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(59,083&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(59,083&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Web development costs, net&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;354,643&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;387,215&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</OPRX:ScheduleOfWebsiteDevelopmentCostsTableTextBlock>
    <OPRX:UsefulLifeOfWebsite contextRef="From2013-01-01to2013-03-31">P5Y</OPRX:UsefulLifeOfWebsite>
    <us-gaap:UnamortizedDebtIssuanceExpense contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">59083</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">59083</us-gaap:UnamortizedDebtIssuanceExpense>
    <OPRX:AmortizationExpenseOfWebsite contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">32572</OPRX:AmortizationExpenseOfWebsite>
    <OPRX:AmortizationExpenseOfWebsite contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">31047</OPRX:AmortizationExpenseOfWebsite>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2013-01-01to2013-03-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April&amp;#160;26, 2010, the Company acquired&#13;from an officer and shareholder the technical contributions and assignment of all exclusive rights to and for the SampleMD patent&#13;currently in process in exchange for 300,000 shares of common stock to be granted at the discretion of the seller in addition to&#13;200,000 stock options valued at $360,000. The shares were valued on the grant date at $570,000 and have been recorded as a payable&#13;to the related party.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has capitalized costs in purchasing&#13;the SampleMD patent, which consisted of the following as of March&amp;#160;31, 2013 and December&amp;#160;31, 2012:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/6pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="border-collapse: collapse; font-size: 10pt; width: 65%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt; width: 54%"&gt;Patent rights and intangible assets&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 20%"&gt;960,368&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 20%"&gt;930,000&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left; padding-left: 5.4pt"&gt;Accumulated amortization&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(150,896&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(136,764&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Patent rights and intangible assets, net&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;809,472&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;793,236&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company began amortizing the patent,&#13;using the straight-line method over the estimated useful life of 17 years, once it was put into service in July 2010. In 2013,&#13;the Company began incurring costs related to defense of the patent. These costs have been capitalized and will be amortized using&#13;the straight-line method over the remaining useful life of the original patent. Amortization expense was $14,132 and $13,676 for&#13;the three months ended March&amp;#160;31, 2013 and 2012, respectively.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="From2013-01-01to2013-03-31">&lt;table cellspacing="0" cellpadding="0" align="center" style="border-collapse: collapse; font-size: 10pt; width: 65%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt; width: 54%"&gt;Patent rights and intangible assets&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 20%"&gt;960,368&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 20%"&gt;930,000&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left; padding-left: 5.4pt"&gt;Accumulated amortization&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(150,896&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(136,764&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Patent rights and intangible assets, net&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;809,472&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;793,236&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <OPRX:AccruedExpenseTextBlock contextRef="From2013-01-01to2013-03-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 14, 2013, the Company hired&#13;a new CEO. The employment agreement requires annual compensation of $175,000 that will be accrued and deferred until at least January&#13;1, 2014. Additionally, the agreement requires the issuance of 2,000,000 options with an exercise price of $1.00 for a term of five&#13;years. The options are not exercisable until at least January 1, 2014. The Company has accrued $43,750, or three months compensation,&#13;at March&amp;#160;31, 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accrued expenses consisted of the following&#13;as of March&amp;#160;31, 2013 and December&amp;#160;31, 2012:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/6pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/6pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="border-collapse: collapse; font-size: 10pt; width: 65%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt; width: 54%"&gt;Accrued compensation&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 20%"&gt;43,750&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 20%"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left; padding-left: 5.4pt"&gt;Accrued audit fees&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;6,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Total accrued expenses&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;43,750&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;6,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</OPRX:AccruedExpenseTextBlock>
    <OPRX:ScheduleOfAccruedExpensesTableTextBlock contextRef="From2013-01-01to2013-03-31">&lt;table cellspacing="0" cellpadding="0" align="center" style="border-collapse: collapse; font-size: 10pt; width: 65%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt; width: 54%"&gt;Accrued compensation&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 20%"&gt;43,750&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 20%"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left; padding-left: 5.4pt"&gt;Accrued audit fees&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;6,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Total accrued expenses&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;43,750&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;6,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</OPRX:ScheduleOfAccruedExpensesTableTextBlock>
    <us-gaap:DeferredRevenueDisclosureTextBlock contextRef="From2013-01-01to2013-03-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has signed several contracts&#13;with customers for either the distribution or redemption of coupons. The payments are not taken into revenue until either the coupon&#13;is distributed to a patient or the coupon has been redeemed depending on the specific contract. The distributions and redemptions&#13;are tracked by the company&amp;#146;s administrative tool. Additionally, customer setup contracts that have been paid in full are&#13;deferred until the Company has completed the obligations of the contacts. Deferred revenue was $80,772 and $49,252 as of March&amp;#160;31,&#13;2013 and December 31, 2012, respectively.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:DeferredRevenueDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2013-01-01to2013-03-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;During the year&#13;ended December&amp;#160;31, 2010, the Company acquired from an officer and shareholder the technical contributions and assignment of&#13;all exclusive rights to and for the SampleMD patent currently in process in exchange for 300,000 shares of common stock to be granted&#13;at the discretion of the seller in addition to 200,000 stock options valued at $360,000. The shares were valued on the grant date&#13;at $570,000 and have been recorded as a payable to the related party.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <OPRX:ShareBasedCompensationArrangementOfStockOptionsIssued contextRef="AsOf2010-12-31" unitRef="Shares" decimals="INF">300000</OPRX:ShareBasedCompensationArrangementOfStockOptionsIssued>
    <OPRX:CommonStockIssuedForPurchaseOfPatent contextRef="AsOf2010-12-31" unitRef="Shares" decimals="INF">200000</OPRX:CommonStockIssuedForPurchaseOfPatent>
    <OPRX:ShareBasedCompensationArrangementOfStockOptionsValue contextRef="AsOf2010-12-31" unitRef="USD" decimals="0">360000</OPRX:ShareBasedCompensationArrangementOfStockOptionsValue>
    <OPRX:CommonStockValueOnGrantDate contextRef="AsOf2010-12-31" unitRef="USD" decimals="0">570000</OPRX:CommonStockValueOnGrantDate>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2013-01-01to2013-03-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;OptimizeRx Corporation has 500,000,000&#13;shares of $.001 par value common stock authorized as of December&amp;#160;31, 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;There were 14,232,496 and 14,232,496 common&#13;shares issued and outstanding at March&amp;#160;31, 2013 and December&amp;#160;31, 2012, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June&amp;#160;1, 2012, the Company entered&#13;into a consulting agreement with North Coast Advisors, Inc. for various services. The Company agreed to issue 40,000 shares of&#13;common stock as of the date of the contract. However, these shares were not issued until July&amp;#160;12, 2012. The Company also agreed&#13;to issue an additional 40,000 shares every six months in alignment with the agreement renewal up to the two years of the agreement.&#13;The first 40,000 shares were valued at the Company&amp;#146;s common stock price as of the date of the contract, which was $1.12/share&#13;and has been expensed. No additional shares were issued as of March 31, 2013.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockTextBlock contextRef="From2013-01-01to2013-03-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;u&gt;Series A Preferred&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December&amp;#160;31,&#13;2008, 35 preferred shares were issued for $3,500,000. Issuance costs totaled $515,000 resulting in net proceeds of $2,985,000.&#13;The 35 shares are convertible to 3,500,000 shares of common stock and bear a 10% cumulative dividend. In addition, there was a&#13;warrant issued to purchase 6,000,000 shares of common stock at an exercise price of $2 for a period of seven years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The holders of the preferred stock are&#13;entitled to semi-annual dividends payable on the stated value of the Series A preferred stock at a rate of 10% per annum, which&#13;shall be cumulative, and accrue daily from the issuance date. The dividends may be paid in cash or shares of the Company's common&#13;stock at management&amp;#146;s discretion. If after the conversion eligibility date, the market price for the common stock for any&#13;ten consecutive trading days in which the stock trades for over $2 per share and trading exceeds 100,000 shares per day, the preferred&#13;shareholders can be required to convert their shares to common stock. Each share of Series A preferred stock shall also be convertible&#13;at the option of the holder into that number of shares of common stock of the Company at the stated value of such share at a $1&#13;conversion price.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The holder may cause this conversion at&#13;the time the shares are eligible for resale by the holder. The conversion price is subject to adjustment as hereinafter provided,&#13;at any time, or from time to time upon the terms and in the manner hereinafter set forth in the shareholder agreement. There is&#13;no conversion expiration date, however, the holder must provide 30 days notice for the registration of the conversion.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;&lt;b&gt;OPTIMIZERx&#13;CORPORATION&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;&lt;b&gt;NOTES&#13;TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;&lt;b&gt;MARCH&amp;#160;31,&#13;2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: left"&gt;NOTE 11 &amp;#150; PREFERRED&#13;STOCK (CONTINUED)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;u&gt;Series A Preferred Continued&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May&amp;#160;12, 2010, the Company&amp;#146;s&#13;Board declared and issued 236,598 common shares as payment for all cumulative and current semi-annual dividends. On November&amp;#160;16,&#13;2010, the Company&amp;#146;s Board declared and issued 173,922 common shares for its semi-annual dividend payment. On March&amp;#160;25,&#13;2011, the Company&amp;#146;s Board declared and issued 176,768 common shares for its semi-annual dividend payment. On September&amp;#160;21,&#13;2011, the Company's Board declared and issued 156,306 common shares for its semi-annual dividend payment. The Company has undeclared&#13;dividends that were due in February and September 2012 totaling $350,000 as of December 31, 2012 and undeclared dividends of $175,000&#13;due in February 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;u&gt;Series B Preferred&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December&amp;#160;31,&#13;2010, 15 preferred shares were issued for $1,500,000. The 15 shares are convertible to 1,500,000 shares of common stock and bear&#13;a 10% cumulative dividend. In addition, there was a warrant issued to purchase 3,000,000 shares of common stock at an exercise&#13;price of $3 for a period of seven years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preferred stock was issued for $1,500,000&#13;less associated issuance costs of $350,000 for net proceeds of $1,150,000. Additionally, 3,000,000 common stock warrants were issued&#13;with the preferred stock. Based on the fair values of the preferred stock and common stock warrants on the issue date, $341,100&#13;was allocated to preferred stock and $1,158,900 was allocated to the common stock warrants. Equity issuance costs of $350,000 were&#13;allocated to the preferred stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the quarter ended September&amp;#160;30,&#13;2011, 15 preferred shares were issued to an investor for $1,500,000. The 15 shares are convertible to 1,500,000 shares of common&#13;stock and bear a 10% cumulative dividend. In addition, there was a warrant issued to purchase 1,000,000 shares of common stock&#13;at an exercise price of $3 for a period of seven years. Based on the fair values of the preferred stock and common stock warrants&#13;on the issue date, $855,460 was allocated to preferred stock and $644,540 was allocated to the common stock warrants. See Note&#13;12.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The holders of the preferred stock are&#13;entitled to semi-annual dividends payable on the stated value of the Series B preferred stock at a rate of 10% per annum, which&#13;shall be cumulative, and accrue daily from the issuance date. The dividends may be paid in cash or shares of the Company's common&#13;stock at management&amp;#146;s discretion. If after the conversion eligibility date, the market price for the common stock for any&#13;ten consecutive trading days in which the stock trades for over $2 per share and trading exceeds 100,000 shares per day, the preferred&#13;shareholders can be required to convert their shares to common stock. Each share of Series B preferred stock shall also be convertible&#13;at the option of the holder into that number of shares of common stock of the Company at the stated value of such share at a $1.50&#13;conversion price.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The holder may cause this conversion at&#13;the time the shares are eligible for resale by the holder. The conversion price is subject to adjustment as hereinafter provided,&#13;at any time, or from time to time upon the terms and in the manner hereinafter set forth in the shareholder agreement. On March&amp;#160;25,&#13;2011, the Company&amp;#146;s Board declared and issued 75,758 common shares for its semi-annual dividend payment. On September&amp;#160;21,&#13;2011, the Company's Board declared and issued 66,988 common shares for its semi-annual dividend payment. The Company has undeclared&#13;dividends that were due in February and September 2012 totaling $150,000 as of December 31, 2012 and undeclared dividends of $75,000&#13;due in February 2013.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:PreferredStockTextBlock>
    <OPRX:StockOptionsWarrantsTextBlock contextRef="From2013-01-01to2013-03-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounts for employee stock-based&#13;compensation in accordance with the guidance of ASC Topic 718: Compensation - Stock Compensation, which requires all share-based&#13;payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their&#13;fair values.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company follows ASC Topic 505-50, formerly&#13;EITF 96-18, &amp;#147;Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with&#13;Selling Goods and Services,&amp;#148; for stock options and warrants issued to consultants and other non-employees. In accordance&#13;with ASC Topic 505-50, these stock options and warrants issued as compensation for services provided to the Company are accounted&#13;for based upon the fair value of the services provided or the estimated fair market value of the option or warrant, whichever can&#13;be more clearly determined. The fair value of the equity instrument is charged directly to compensation expense and additional&#13;paid-in capital over the period during which services are rendered.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May&amp;#160;31, 2011, the Company issued&#13;285,000 stock options to 3 employees at an exercise price of $1.00. The options were valued on the grant date using the Black-Scholes&#13;option-pricing model with the following assumptions: dividend yield of 0%, expected volatility of 218%, risk-free interest rate&#13;of 1.68% and expected life of 60 months. The total value of the options was $320,585. The options vest over one year. The Company&#13;recognized share-based compensation expense of $187,005 during the year ended December 31, 2011. The remaining balance of $133,580&#13;was recognized over the first five months of 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the quarter ended December&amp;#160;31,&#13;2011, the Company issued 20,000 stock options to 2 employees at an exercise price of $1.00. The options were valued on the grant&#13;date using the Black-Scholes option-pricing model with the following assumptions: dividend yield of 0%, expected volatility of&#13;204-205%, risk-free interest rate of 0.88-0.93% and expected life of 60 months. The total value of the options was $19,270. The&#13;options vest over one year. &lt;font style="color: black; background-color: white"&gt;&amp;#160;&lt;/font&gt;&lt;font style="background-color: white"&gt;The&#13;Company&lt;font style="color: black"&gt;&amp;#160;recognized share-based compensation expense of $2,480 during the year ended&amp;#160;&lt;/font&gt;December&#13;31,&amp;#160;2011&amp;#160;a&lt;font style="color: black"&gt;nd $4,818 during the &lt;/font&gt;quarter ended March&amp;#160;31, 2012&lt;font style="color: black"&gt;.&#13;The remaining balance was recognized during the remainder of 2012.&amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November&amp;#160;21, 2011, the Company&#13;issued 100,000 stock options to an individual at an exercise price of $0.73. The options were valued on the grant date using the&#13;Black-Scholes option-pricing model with the following assumptions: dividend yield of 0%, expected volatility of 205%, risk-free&#13;interest rate of 0.92% and expected life of 60 months. &lt;font style="background-color: white"&gt;&amp;#160;The Company&amp;#160;recognized&#13;expenses of $8,346 during the year ended&amp;#160;December&amp;#160;31, 2011&amp;#160;and $25,039 during the quarter ended&amp;#160;March&amp;#160;31,&#13;2012. The remaining balance was recognized during the remainder of 2012.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the quarter ended March&amp;#160;31,&#13;2012, the Company issued 50,000 stock options to 4 non-employees at an exercise price of $0.89. The options were valued on the&#13;grant date using the Black-Scholes option-pricing model with the following assumptions: dividend yield of 0%, expected volatility&#13;of 198%, risk-free interest rate of 0.65% and expected life of 48 months. The total value of the options was $35,091. The options&#13;vest over 4 months. The Company recognized share-based compensation expense of $17,546 during the three months ended March 31,&#13;2012. The balance was expensed during the three months ended June 30, 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;&lt;b&gt;OPTIMIZERx&#13;CORPORATION&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;&lt;b&gt;NOTES&#13;TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;&lt;b&gt;MARCH&amp;#160;31,&#13;2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: left"&gt;NOTE 12 &amp;#150; STOCK&#13;OPTIONS AND WARRANTS (CONTINUED)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the quarter ended December&amp;#160;31,&#13;2012, the Company issued 25,000 stock options to a non-employee at an exercise price of $1.58. The options were valued on the grant&#13;date using the Black-Scholes option-pricing model with the following assumptions: dividend yield of 0%, expected volatility of&#13;200%, risk-free interest rate of 0.67% and expected life of 60 months. The total value of the options was $40,007. The options&#13;vest over 1 year. The Company recognized share-based compensation expense of $8,335 during the three months ended December&amp;#160;31,&#13;2012 and $10,002 during the three months ended March 31, 2013. The remaining balance will be recognized over the remainder of 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company had the following options outstanding&#13;as of March 31, 2013:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="border-collapse: collapse; font-size: 10pt; width: 65%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;Number of Options&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;Weighted average exercise price&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 31%; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Outstanding, January 1, 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 31%"&gt;405,000&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 30%"&gt;1.01&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Granted - 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;75,000&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.17&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Exercised - 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Expired - 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(455,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(.98&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Balance, December 31, 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;25,000&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.58&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Granted - 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Exercised - 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Expired - 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Balance, March 31, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;25,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;1.58&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company had the following warrants&#13;outstanding as of March 31, 2013:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="border-collapse: collapse; font-size: 10pt; width: 65%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;Number of Warrants&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;Weighted average exercise price&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 31%; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Outstanding, January 1, 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 31%"&gt;14,344,434&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 30%"&gt;2.41&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Granted - 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Exercised - 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Expired - 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Balance, December 31, 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;14,344,434&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.41&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Granted - 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Exercised - 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Expired - 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Balance, March 31, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;14,344,434&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;2.41&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</OPRX:StockOptionsWarrantsTextBlock>
    <OPRX:ScheduleOfOptionsTextBlock contextRef="From2013-01-01to2013-03-31">&lt;table cellspacing="0" cellpadding="0" align="center" style="border-collapse: collapse; font-size: 10pt; width: 65%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;Number of Options&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;Weighted average exercise price&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 31%; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Outstanding, January 1, 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 31%"&gt;405,000&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 30%"&gt;1.01&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Granted - 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;75,000&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.17&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Exercised - 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Expired - 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(455,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(.98&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Balance, December 31, 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;25,000&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.58&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Granted - 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Exercised - 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Expired - 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Balance, March 31, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;25,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;1.58&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</OPRX:ScheduleOfOptionsTextBlock>
    <OPRX:ScheduleOfWarrantsTextBlock contextRef="From2013-01-01to2013-03-31">&lt;table cellspacing="0" cellpadding="0" align="center" style="border-collapse: collapse; font-size: 10pt; width: 65%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;Number of Warrants&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;Weighted average exercise price&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 31%; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Outstanding, January 1, 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 31%"&gt;14,344,434&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 30%"&gt;2.41&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Granted - 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Exercised - 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Expired - 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Balance, December 31, 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;14,344,434&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.41&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Granted - 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Exercised - 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Expired - 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Balance, March 31, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;14,344,434&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;2.41&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</OPRX:ScheduleOfWarrantsTextBlock>
    <us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock contextRef="From2013-01-01to2013-03-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company signed a lease for new office&#13;space on December 1, 2011 at an approximate rent of $5,000 per month. The new offices are in Rochester, Michigan. The lease is&#13;for three years with an option to renew for an additional two years at approximately $5,200 per month with six months advance notice&#13;to exercise the option. Minimum annual rent is as follows for the initial term of the lease:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="border-collapse: collapse; font-size: 10pt; width: 45%"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 68%; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;Year ended December 31, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 27%"&gt;60,591&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;2014&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;55,542&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;2015&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Total lease commitment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;116,133&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
    <us-gaap:ScheduleOfRentExpenseTableTextBlock contextRef="From2013-01-01to2013-03-31">&lt;table cellspacing="0" cellpadding="0" align="center" style="border-collapse: collapse; font-size: 10pt; width: 45%"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 68%; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;Year ended December 31, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 27%"&gt;60,591&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;2014&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;55,542&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;2015&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Total lease commitment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;116,133&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfRentExpenseTableTextBlock>
    <OPRX:MajorCustomersTextBlock contextRef="From2013-01-01to2013-03-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;The Company had&#13;three major customers that accounted for 72% and four major customers that accounted for 74% of the Company&amp;#146;s revenues for&#13;the three months ended March&amp;#160;31, 2013 and 2012, respectively. The Company expects to continue to maintain these relationships&#13;with the customers.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</OPRX:MajorCustomersTextBlock>
    <OPRX:MajorCustomers contextRef="From2013-01-01to2013-03-31" unitRef="Percent" decimals="INF">0.72</OPRX:MajorCustomers>
    <OPRX:MajorCustomers contextRef="From2012-01-01to2012-03-31" unitRef="Percent" decimals="INF">0.74</OPRX:MajorCustomers>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2013-01-01to2013-03-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the three months ended March&amp;#160;31,&#13;2013, the Company incurred a net loss of approximately $105,000 and therefore has no tax liability. The Company began operations&#13;in 2007 and has previous net operating loss carry-forwards of $13,843,000 through December&amp;#160;31, 2012. The cumulative loss of&#13;$13,948,000 will be carried forward and can be used through the year 2033 to offset future taxable income. In the future, the cumulative&#13;net operating loss carry-forward for income tax purposes may differ from the cumulative financial statement loss due to timing&#13;differences between book and tax reporting.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The provision for Federal income tax consists&#13;of the following for the three months ended March&amp;#160;31, 2013 and 2012:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="border-collapse: collapse; font-size: 10pt; width: 65%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Federal income tax benefit attributable to:&lt;/td&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left; width: 54%"&gt;&amp;#160;&amp;#160;Current operations&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 20%"&gt;36,000&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 20%"&gt;102,000&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&amp;#160;Valuation allowance&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(36,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(102,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Net provision for federal income tax&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The cumulative tax effect at the expected&#13;rate of 34% of significant items comprising our net deferred tax amount is as follows as of March&amp;#160;31, 2013 and December&amp;#160;31,&#13;2012:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="border-collapse: collapse; font-size: 10pt; width: 65%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Deferred tax asset attributable to:&lt;/td&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left; width: 54%"&gt;&amp;#160;&amp;#160;Net operating loss carryover&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 20%"&gt;4,742,000&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 20%"&gt;4,706,000&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&amp;#160;Valuation allowance&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(4,742,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(4,706,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Net deferred tax asset&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Due to the change in ownership provisions&#13;of the Tax Reform Act of 1986, net operating loss carry forwards of approximately $13,948,000 for Federal income tax reporting&#13;purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carry forwards may be limited&#13;as to use in future years.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2013-01-01to2013-03-31">&lt;table cellspacing="0" cellpadding="0" align="center" style="border-collapse: collapse; font-size: 10pt; width: 65%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Federal income tax benefit attributable to:&lt;/td&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left; width: 54%"&gt;&amp;#160;&amp;#160;Current operations&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 20%"&gt;36,000&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 20%"&gt;102,000&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&amp;#160;Valuation allowance&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(36,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(102,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Net provision for federal income tax&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2013-01-01to2013-03-31">&lt;table cellspacing="0" cellpadding="0" align="center" style="border-collapse: collapse; font-size: 10pt; width: 65%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Deferred tax asset attributable to:&lt;/td&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="text-align: left; width: 54%"&gt;&amp;#160;&amp;#160;Net operating loss carryover&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 20%"&gt;4,742,000&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 20%"&gt;4,706,000&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&amp;#160;Valuation allowance&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(4,742,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(4,706,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Net deferred tax asset&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">13948000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">13843000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardExpirationDate contextRef="From2013-01-01to2013-03-31">2033-01-01</us-gaap:TaxCreditCarryforwardExpirationDate>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2013-01-01to2013-03-31" unitRef="Percent" decimals="INF">0.34</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <OPRX:OperatingLossCarryForward contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">105000</OPRX:OperatingLossCarryForward>
    <OPRX:ContingentLiabilityTextBlock contextRef="From2013-01-01to2013-03-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 14, 2013, the Company hired&#13;a new CEO. The employment agreement requires annual compensation of $175,000 that will be accrued and deferred until at least January&#13;1, 2014. Additionally, the agreement requires the issuance of 2,000,000 options with an exercise price of $1.00 for a term of five&#13;years. The options are not exercisable until at least January 1, 2014, and are only exercisable after reaching certain financial&#13;terms and conditions. Due to these restrictions, no accrual has been made for the issuance of these options.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</OPRX:ContingentLiabilityTextBlock>
    <OPRX:OperatingExpensesTextBlock contextRef="From2013-01-01to2013-03-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Operating expenses consisted of the following&#13;for the three months ended March 31, 2013 and 2012, respectively:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="border-collapse: collapse; font-size: 10pt; width: 65%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-left: 5.4pt; width: 54%"&gt;Advertising&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 20%"&gt;3,340&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 20%"&gt;11,270&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Professional fees&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;53,098&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;38,003&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Consulting&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;20,407&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;6,615&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Salaries, wages and benefits&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;375,071&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;306,895&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Rent&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;15,148&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;16,918&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Depreciation and amortization&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;48,111&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;46,023&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Stock-based compensation&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;10,002&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;127,548&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Revenue share expense&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;40,203&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left; padding-left: 5.4pt"&gt;General and administrative&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;208,792&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;77,050&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 5.4pt"&gt;Total Operating Expenses&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;774,172&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;630,322&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</OPRX:OperatingExpensesTextBlock>
    <OPRX:ScheduleOfOperatingCostAndExpenseByComponentTextBlock contextRef="From2013-01-01to2013-03-31">&lt;table cellspacing="0" cellpadding="0" align="center" style="border-collapse: collapse; font-size: 10pt; width: 65%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-left: 5.4pt; width: 54%"&gt;Advertising&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 20%"&gt;3,340&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 20%"&gt;11,270&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Professional fees&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;53,098&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;38,003&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Consulting&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;20,407&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;6,615&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Salaries, wages and benefits&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;375,071&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;306,895&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Rent&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;15,148&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;16,918&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Depreciation and amortization&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;48,111&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;46,023&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Stock-based compensation&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;10,002&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;127,548&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Revenue share expense&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;40,203&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left; padding-left: 5.4pt"&gt;General and administrative&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;208,792&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;77,050&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 5.4pt"&gt;Total Operating Expenses&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;774,172&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;630,322&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</OPRX:ScheduleOfOperatingCostAndExpenseByComponentTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2013-01-01to2013-03-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.1pt; text-align: justify"&gt;In accordance with&#13;ASC 855-10, the Company has analyzed its operations subsequent to March&amp;#160;31, 2013 through the date these financial statements&#13;were issued and has determined that it does not have any material subsequent events to disclose in these financial statements other&#13;than the events described above.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <OPRX:Insurance contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">5617</OPRX:Insurance>
    <OPRX:Insurance contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">6437</OPRX:Insurance>
    <OPRX:Rent contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">5049</OPRX:Rent>
    <OPRX:Rent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">5049</OPRX:Rent>
    <OPRX:ConsultingExpense contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">21670</OPRX:ConsultingExpense>
    <OPRX:ConsultingExpense contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">31672</OPRX:ConsultingExpense>
    <OPRX:LegalCosts contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">0</OPRX:LegalCosts>
    <OPRX:LegalCosts contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">25000</OPRX:LegalCosts>
    <OPRX:ComputerEquipmentGross contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">22360</OPRX:ComputerEquipmentGross>
    <OPRX:ComputerEquipmentGross contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">22360</OPRX:ComputerEquipmentGross>
    <us-gaap:FurnitureAndFixturesGross contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">11088</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:FurnitureAndFixturesGross contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">11088</us-gaap:FurnitureAndFixturesGross>
    <OPRX:SubtotalOfPropertyEquipmentCost contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">33448</OPRX:SubtotalOfPropertyEquipmentCost>
    <OPRX:SubtotalOfPropertyEquipmentCost contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">33448</OPRX:SubtotalOfPropertyEquipmentCost>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">-14170</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">-12763</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <OPRX:WebsiteDevelopmentCost1 contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">154133</OPRX:WebsiteDevelopmentCost1>
    <OPRX:WebsiteDevelopmentCost1 contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">154133</OPRX:WebsiteDevelopmentCost1>
    <OPRX:WebsiteDevelopmentCost2 contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">602517</OPRX:WebsiteDevelopmentCost2>
    <OPRX:WebsiteDevelopmentCost2 contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">602517</OPRX:WebsiteDevelopmentCost2>
    <OPRX:SubtotalofWebsiteDevelopmentCosts contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">756650</OPRX:SubtotalofWebsiteDevelopmentCosts>
    <OPRX:SubtotalofWebsiteDevelopmentCosts contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">756650</OPRX:SubtotalofWebsiteDevelopmentCosts>
    <us-gaap:AccumulatedAmortizationOfOtherDeferredCosts contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">-342924</us-gaap:AccumulatedAmortizationOfOtherDeferredCosts>
    <us-gaap:AccumulatedAmortizationOfOtherDeferredCosts contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">-310352</us-gaap:AccumulatedAmortizationOfOtherDeferredCosts>
    <OPRX:WebsiteDevelopmenCostNet contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">354643</OPRX:WebsiteDevelopmenCostNet>
    <OPRX:WebsiteDevelopmenCostNet contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">387215</OPRX:WebsiteDevelopmenCostNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetAmount contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">960368</us-gaap:AcquiredFiniteLivedIntangibleAssetAmount>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetAmount contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">930000</us-gaap:AcquiredFiniteLivedIntangibleAssetAmount>
    <OPRX:AccumulatedAmortizationOfPatentRights contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">-150896</OPRX:AccumulatedAmortizationOfPatentRights>
    <OPRX:AccumulatedAmortizationOfPatentRights contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">-136764</OPRX:AccumulatedAmortizationOfPatentRights>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">809472</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">793236</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <OPRX:AccruedCompensation contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">43750</OPRX:AccruedCompensation>
    <OPRX:AccruedCompensation contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">0</OPRX:AccruedCompensation>
    <OPRX:AccruedAuditFees contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">0</OPRX:AccruedAuditFees>
    <OPRX:AccruedAuditFees contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">6000</OPRX:AccruedAuditFees>
    <OPRX:AccruedExpenses contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">43750</OPRX:AccruedExpenses>
    <OPRX:AccruedExpenses contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">6000</OPRX:AccruedExpenses>
    <OPRX:OptionsIssued contextRef="AsOf2013-03-31" unitRef="Shares" decimals="INF">25000</OPRX:OptionsIssued>
    <OPRX:OptionsIssued contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">405000</OPRX:OptionsIssued>
    <OPRX:OptionsIssued contextRef="AsOf2012-03-31" unitRef="Shares" decimals="INF">25000</OPRX:OptionsIssued>
    <OPRX:OptionIssuedPrice contextRef="AsOf2013-03-31" unitRef="USDPShares" decimals="INF">1.58</OPRX:OptionIssuedPrice>
    <OPRX:OptionIssuedPrice contextRef="AsOf2011-12-31" unitRef="USDPShares" decimals="INF">1.01</OPRX:OptionIssuedPrice>
    <OPRX:OptionIssuedPrice contextRef="AsOf2012-03-31" unitRef="USDPShares" decimals="INF">1.58</OPRX:OptionIssuedPrice>
    <OPRX:OptionsGranted contextRef="From2013-01-01to2013-03-31" unitRef="Shares" decimals="INF">0</OPRX:OptionsGranted>
    <OPRX:OptionsGranted contextRef="From2012-01-01to2012-03-31" unitRef="Shares" decimals="INF">75000</OPRX:OptionsGranted>
    <OPRX:OptionGrantedPrice contextRef="From2013-01-01to2013-03-31" unitRef="USDPShares" decimals="INF">0</OPRX:OptionGrantedPrice>
    <OPRX:OptionGrantedPrice contextRef="From2012-01-01to2012-03-31" unitRef="USDPShares" decimals="INF">1.17</OPRX:OptionGrantedPrice>
    <OPRX:OptionsExercised contextRef="From2013-01-01to2013-03-31" unitRef="Shares" decimals="INF">0</OPRX:OptionsExercised>
    <OPRX:OptionsExercised contextRef="From2012-01-01to2012-03-31" unitRef="Shares" decimals="INF">0</OPRX:OptionsExercised>
    <OPRX:OptionExercisedPrice contextRef="From2013-01-01to2013-03-31" unitRef="USDPShares" decimals="INF">0</OPRX:OptionExercisedPrice>
    <OPRX:OptionExercisedPrice contextRef="From2012-01-01to2012-03-31" unitRef="USDPShares" decimals="INF">0</OPRX:OptionExercisedPrice>
    <OPRX:OptionsExpired contextRef="From2013-01-01to2013-03-31" unitRef="Shares" decimals="INF">0</OPRX:OptionsExpired>
    <OPRX:OptionsExpired contextRef="From2012-01-01to2012-03-31" unitRef="Shares" decimals="INF">-455000</OPRX:OptionsExpired>
    <OPRX:OptionExpiredPrice contextRef="From2013-01-01to2013-03-31" unitRef="USDPShares" decimals="INF">0</OPRX:OptionExpiredPrice>
    <OPRX:OptionExpiredPrice contextRef="From2012-01-01to2012-03-31" unitRef="USDPShares" decimals="INF">-.98</OPRX:OptionExpiredPrice>
    <OPRX:WarrantsIssued contextRef="AsOf2013-03-31" unitRef="Shares" decimals="INF">14344434</OPRX:WarrantsIssued>
    <OPRX:WarrantsIssued contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">14344434</OPRX:WarrantsIssued>
    <OPRX:WarrantsIssued contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">14344434</OPRX:WarrantsIssued>
    <OPRX:WarrantsIssued contextRef="AsOf2012-03-31" unitRef="Shares" decimals="INF">14344434</OPRX:WarrantsIssued>
    <OPRX:WarrantsIssuedPrice contextRef="AsOf2013-03-31" unitRef="USDPShares" decimals="INF">2.41</OPRX:WarrantsIssuedPrice>
    <OPRX:WarrantsIssuedPrice contextRef="AsOf2012-12-31" unitRef="USDPShares" decimals="INF">2.41</OPRX:WarrantsIssuedPrice>
    <OPRX:WarrantsIssuedPrice contextRef="AsOf2011-12-31" unitRef="USDPShares" decimals="INF">2.41</OPRX:WarrantsIssuedPrice>
    <OPRX:WarrantsIssuedPrice contextRef="AsOf2012-03-31" unitRef="USDPShares" decimals="INF">2.41</OPRX:WarrantsIssuedPrice>
    <OPRX:WarrantsGranted contextRef="From2013-01-01to2013-03-31" unitRef="Shares" decimals="INF">0</OPRX:WarrantsGranted>
    <OPRX:WarrantsGranted contextRef="From2012-01-01to2012-03-31" unitRef="Shares" decimals="INF">0</OPRX:WarrantsGranted>
    <OPRX:WarrantsGrantedPrice contextRef="From2013-01-01to2013-03-31" unitRef="USDPShares" decimals="INF">0</OPRX:WarrantsGrantedPrice>
    <OPRX:WarrantsGrantedPrice contextRef="From2012-01-01to2012-03-31" unitRef="USDPShares" decimals="INF">0</OPRX:WarrantsGrantedPrice>
    <OPRX:WarrantsExercised contextRef="From2013-01-01to2013-03-31" unitRef="Shares" decimals="INF">0</OPRX:WarrantsExercised>
    <OPRX:WarrantsExercised contextRef="From2012-01-01to2012-03-31" unitRef="Shares" decimals="INF">0</OPRX:WarrantsExercised>
    <OPRX:WarrantsExercisedPrice contextRef="From2013-01-01to2013-03-31" unitRef="USDPShares" decimals="INF">0</OPRX:WarrantsExercisedPrice>
    <OPRX:WarrantsExercisedPrice contextRef="From2012-01-01to2012-03-31" unitRef="USDPShares" decimals="INF">0</OPRX:WarrantsExercisedPrice>
    <OPRX:WarrantsExpired contextRef="From2013-01-01to2013-03-31" unitRef="Shares" decimals="INF">0</OPRX:WarrantsExpired>
    <OPRX:WarrantsExpired contextRef="From2012-01-01to2012-03-31" unitRef="Shares" decimals="INF">0</OPRX:WarrantsExpired>
    <OPRX:WarrantsExpiredPrice contextRef="From2013-01-01to2013-03-31" unitRef="USDPShares" decimals="INF">0</OPRX:WarrantsExpiredPrice>
    <OPRX:WarrantsExpiredPrice contextRef="From2012-01-01to2012-03-31" unitRef="USDPShares" decimals="INF">0</OPRX:WarrantsExpiredPrice>
    <OPRX:MinimumAnnualLeaseAmountDue contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">60591</OPRX:MinimumAnnualLeaseAmountDue>
    <OPRX:MinimumAnnualLeaseAmountDue contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">55542</OPRX:MinimumAnnualLeaseAmountDue>
    <OPRX:MinimumAnnualLeaseAmountDue contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">0</OPRX:MinimumAnnualLeaseAmountDue>
    <OPRX:TotalLeaseCommitmentDue contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">116133</OPRX:TotalLeaseCommitmentDue>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">36000</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">102000</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">-36000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">-102000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <OPRX:NetFederalIncomeTax contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">0</OPRX:NetFederalIncomeTax>
    <OPRX:NetFederalIncomeTax contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">0</OPRX:NetFederalIncomeTax>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">4742000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">4706000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">-4742000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">-4706000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:AdvertisingExpense contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">3340</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">11270</us-gaap:AdvertisingExpense>
    <us-gaap:ProfessionalFees contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">53098</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">38003</us-gaap:ProfessionalFees>
    <OPRX:Consulting contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">20407</OPRX:Consulting>
    <OPRX:Consulting contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">6615</OPRX:Consulting>
    <us-gaap:SalariesWagesAndOfficersCompensation contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">375071</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">306895</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:PaymentsForRent contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">15148</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">16918</us-gaap:PaymentsForRent>
    <us-gaap:ShareBasedCompensation contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">10002</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">127548</us-gaap:ShareBasedCompensation>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">208792</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">77050</us-gaap:GeneralAndAdministrativeExpense>
    <OPRX:RevenueShareExpense contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">40203</OPRX:RevenueShareExpense>
    <OPRX:RevenueShareExpense contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">0</OPRX:RevenueShareExpense>
    <OPRX:EntityIncorporationDateOfOrganization contextRef="From2013-01-01to2013-03-31">2006-01-31</OPRX:EntityIncorporationDateOfOrganization>
    <dei:EntityIncorporationDateOfIncorporation contextRef="From2013-01-01to2013-03-31">2007-10-22</dei:EntityIncorporationDateOfIncorporation>
    <OPRX:CapitalStockOfOptimizerxCorporationExchangedForCommonStockOfRFID contextRef="AsOf2008-04-14" unitRef="Shares" decimals="INF">1256958</OPRX:CapitalStockOfOptimizerxCorporationExchangedForCommonStockOfRFID>
    <OPRX:Ownership contextRef="AsOf2008-04-14" unitRef="Percent" decimals="INF">1.00</OPRX:Ownership>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <OPRX:CapitalAssetsUsefulLifeMinimum contextRef="From2013-01-01to2013-03-31">P3Y</OPRX:CapitalAssetsUsefulLifeMinimum>
    <OPRX:CapitalAssetsUsefulLifeMaximum contextRef="From2013-01-01to2013-03-31">P7Y</OPRX:CapitalAssetsUsefulLifeMaximum>
    <OPRX:UsefulLifeOfPatent contextRef="From2013-01-01to2013-03-31">P17Y</OPRX:UsefulLifeOfPatent>
    <OPRX:AmortizationExpenseofPatent contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">14132</OPRX:AmortizationExpenseofPatent>
    <OPRX:AmortizationExpenseofPatent contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">13676</OPRX:AmortizationExpenseofPatent>
    <OPRX:CommonStockSharesGrantedToAcquireExclusivePatentRights contextRef="AsOf2010-04-26" unitRef="Shares" decimals="INF">300000</OPRX:CommonStockSharesGrantedToAcquireExclusivePatentRights>
    <OPRX:OptionsGrantedToAcquireExclusivePatentRights contextRef="AsOf2010-04-26" unitRef="Shares" decimals="INF">200000</OPRX:OptionsGrantedToAcquireExclusivePatentRights>
    <OPRX:OptionsGrantedToAcquireExclusivePatentRightsValue contextRef="AsOf2010-04-26" unitRef="USD" decimals="0">360000</OPRX:OptionsGrantedToAcquireExclusivePatentRightsValue>
    <OPRX:CommonStockSharesGrantedToAcquireExclusivePatentRightsValue contextRef="AsOf2010-04-26" unitRef="USD" decimals="0">570000</OPRX:CommonStockSharesGrantedToAcquireExclusivePatentRightsValue>
    <OPRX:AnnualCompensationForCeo contextRef="AsOf2013-01-14" unitRef="USD" decimals="0">175000</OPRX:AnnualCompensationForCeo>
    <OPRX:ExercisableDate contextRef="AsOf2013-01-14">2014-01-01</OPRX:ExercisableDate>
    <OPRX:TermOfOptionsAgreement contextRef="AsOf2013-01-14">P5Y</OPRX:TermOfOptionsAgreement>
    <OPRX:IssuanceOfStockOptionsToCeoShares contextRef="AsOf2013-01-14" unitRef="Shares" decimals="INF">2000000</OPRX:IssuanceOfStockOptionsToCeoShares>
    <OPRX:IssuanceOfStockOptionsToCeoParValue contextRef="AsOf2013-01-14" unitRef="USDPShares" decimals="INF">1</OPRX:IssuanceOfStockOptionsToCeoParValue>
    <OPRX:StockIssuedUnderConsultingAgreement contextRef="AsOf2012-07-12" unitRef="Shares" decimals="INF">40000</OPRX:StockIssuedUnderConsultingAgreement>
    <OPRX:StockIssuedUnderConsultingAgreementParValue contextRef="AsOf2012-07-12" unitRef="USDPShares" decimals="INF">1.12</OPRX:StockIssuedUnderConsultingAgreementParValue>
    <OPRX:StockGrantedDuringPeriodSharesUnderConsultingAgreementEverySixMonths contextRef="AsOf2012-06-30" unitRef="Shares" decimals="INF">40000</OPRX:StockGrantedDuringPeriodSharesUnderConsultingAgreementEverySixMonths>
    <OPRX:TermOfConsultingAgreement contextRef="AsOf2012-06-30">P2Y</OPRX:TermOfConsultingAgreement>
    <OPRX:PreferredStockSeriesASharesIssuedForProceeds contextRef="From2008-01-01to2008-12-31" unitRef="Shares" decimals="INF">35</OPRX:PreferredStockSeriesASharesIssuedForProceeds>
    <OPRX:PreferredStockSeriesAValue contextRef="From2008-01-01to2008-12-31" unitRef="USD" decimals="0">3500000</OPRX:PreferredStockSeriesAValue>
    <OPRX:PreferredStockSeriesAStockIssuanceExpense contextRef="From2008-01-01to2008-12-31" unitRef="USD" decimals="0">515000</OPRX:PreferredStockSeriesAStockIssuanceExpense>
    <OPRX:PreferredStockSeriesAStockNetProceeds contextRef="From2008-01-01to2008-12-31" unitRef="USD" decimals="0">2985000</OPRX:PreferredStockSeriesAStockNetProceeds>
    <OPRX:ConvertiblePreferredStockSeriesASharesIssuedUponConversion contextRef="From2008-01-01to2008-12-31" unitRef="Shares" decimals="INF">3500000</OPRX:ConvertiblePreferredStockSeriesASharesIssuedUponConversion>
    <OPRX:PreferredStockSeriesAStockDividendRatePercentage contextRef="From2008-01-01to2008-12-31" unitRef="Percent" decimals="INF">0.10</OPRX:PreferredStockSeriesAStockDividendRatePercentage>
    <OPRX:CommonStockWarrantsIssuedForPurchase contextRef="From2008-01-01to2008-12-31" unitRef="Shares" decimals="INF">6000000</OPRX:CommonStockWarrantsIssuedForPurchase>
    <OPRX:CommonStockWarrantsIssuedForPurchase contextRef="From2010-01-01to2010-12-31" unitRef="Shares" decimals="INF">3000000</OPRX:CommonStockWarrantsIssuedForPurchase>
    <OPRX:CommonStockWarrantsExercisePrice contextRef="From2008-01-01to2008-12-31" unitRef="USDPShares" decimals="INF">2</OPRX:CommonStockWarrantsExercisePrice>
    <OPRX:CommonStockWarrantsExercisePrice contextRef="From2010-01-01to2010-12-31" unitRef="USDPShares" decimals="INF">3</OPRX:CommonStockWarrantsExercisePrice>
    <OPRX:CommonStockWarrantsExpiration contextRef="From2008-01-01to2008-12-31">P7Y</OPRX:CommonStockWarrantsExpiration>
    <OPRX:CommonStockWarrantsExpiration contextRef="From2010-01-01to2010-12-31">P7Y</OPRX:CommonStockWarrantsExpiration>
    <OPRX:CommonStockSharesIssuedForDividendPaymentForSeriesA contextRef="AsOf2010-05-12" unitRef="Shares" decimals="INF">236598</OPRX:CommonStockSharesIssuedForDividendPaymentForSeriesA>
    <OPRX:CommonStockSharesIssuedForDividendPaymentForSeriesA contextRef="AsOf2010-11-16" unitRef="Shares" decimals="INF">173922</OPRX:CommonStockSharesIssuedForDividendPaymentForSeriesA>
    <OPRX:CommonStockSharesIssuedForDividendPaymentForSeriesA contextRef="AsOf2011-03-25" unitRef="Shares" decimals="INF">176768</OPRX:CommonStockSharesIssuedForDividendPaymentForSeriesA>
    <OPRX:CommonStockSharesIssuedForDividendPaymentForSeriesA contextRef="AsOf2011-09-21" unitRef="Shares" decimals="INF">156306</OPRX:CommonStockSharesIssuedForDividendPaymentForSeriesA>
    <OPRX:PreferredStockSeriesBSharesIssuedForProceeds contextRef="From2010-01-01to2010-12-31" unitRef="Shares" decimals="INF">15</OPRX:PreferredStockSeriesBSharesIssuedForProceeds>
    <OPRX:PreferredStockSeriesBValue contextRef="From2010-01-01to2010-12-31" unitRef="USD" decimals="0">1500000</OPRX:PreferredStockSeriesBValue>
    <OPRX:ConvertiblePreferredStockSeriesBSharesIssuedUponConversion contextRef="From2010-01-01to2010-12-31" unitRef="Shares" decimals="INF">1500000</OPRX:ConvertiblePreferredStockSeriesBSharesIssuedUponConversion>
    <OPRX:PreferredStockSeriesBStockDividendRatePercentage contextRef="From2010-01-01to2010-12-31" unitRef="Percent" decimals="INF">0.10</OPRX:PreferredStockSeriesBStockDividendRatePercentage>
    <OPRX:PreferredStockSeriesBStockIssuanceExpense contextRef="From2010-01-01to2010-12-31" unitRef="USD" decimals="0">350000</OPRX:PreferredStockSeriesBStockIssuanceExpense>
    <OPRX:PreferredStockSeriesBStockNetProceeds contextRef="From2010-01-01to2010-12-31" unitRef="USD" decimals="0">1150000</OPRX:PreferredStockSeriesBStockNetProceeds>
    <OPRX:CommonStockWarrantsIssued contextRef="From2010-01-01to2010-12-31" unitRef="Shares" decimals="INF">3000000</OPRX:CommonStockWarrantsIssued>
    <OPRX:PreferredStockValueOnGrantDate contextRef="From2010-01-01to2010-12-31" unitRef="USD" decimals="0">341100</OPRX:PreferredStockValueOnGrantDate>
    <OPRX:CommonStockWarrantValueOnGrantDate contextRef="From2010-01-01to2010-12-31" unitRef="USD" decimals="0">1158900</OPRX:CommonStockWarrantValueOnGrantDate>
    <OPRX:CommonStockSharesIssuedForDividendPaymentForSeriesB contextRef="AsOf2011-03-25" unitRef="Shares" decimals="INF">75758</OPRX:CommonStockSharesIssuedForDividendPaymentForSeriesB>
    <OPRX:CommonStockSharesIssuedForDividendPaymentForSeriesB contextRef="AsOf2011-09-21" unitRef="Shares" decimals="INF">66988</OPRX:CommonStockSharesIssuedForDividendPaymentForSeriesB>
    <OPRX:UndeclaredDividendsPreferredStockValue contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">150000</OPRX:UndeclaredDividendsPreferredStockValue>
    <OPRX:UndeclaredDividendsPreferredStockValue contextRef="AsOf2013-02-28" unitRef="USD" decimals="0">75000</OPRX:UndeclaredDividendsPreferredStockValue>
    <OPRX:StockOptionVestingPeriod contextRef="AsOf2012-12-31">P1Y</OPRX:StockOptionVestingPeriod>
    <OPRX:StockOptionVestingPeriod contextRef="AsOf2012-03-31">P4M</OPRX:StockOptionVestingPeriod>
    <OPRX:StockOptionVestingPeriod contextRef="AsOf2011-05-31">P1Y</OPRX:StockOptionVestingPeriod>
    <OPRX:StockOptionExercisePricePerShare contextRef="AsOf2012-12-31" unitRef="USDPShares" decimals="INF">1.58</OPRX:StockOptionExercisePricePerShare>
    <OPRX:StockOptionExercisePricePerShare contextRef="AsOf2012-03-31" unitRef="USDPShares" decimals="INF">0.89</OPRX:StockOptionExercisePricePerShare>
    <OPRX:StockOptionExercisePricePerShare contextRef="AsOf2011-05-31" unitRef="USDPShares" decimals="INF">1.00</OPRX:StockOptionExercisePricePerShare>
    <OPRX:StockOptionExercisePricePerShare contextRef="AsOf2011-11-21" unitRef="USDPShares" decimals="INF">0.73</OPRX:StockOptionExercisePricePerShare>
    <OPRX:IndividualStockOptionIssuance contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">25000</OPRX:IndividualStockOptionIssuance>
    <OPRX:IndividualStockOptionIssuance contextRef="AsOf2012-03-31" unitRef="Shares" decimals="INF">50000</OPRX:IndividualStockOptionIssuance>
    <OPRX:IndividualStockOptionIssuance contextRef="AsOf2011-11-21" unitRef="Shares" decimals="INF">100000</OPRX:IndividualStockOptionIssuance>
    <OPRX:IndividualStockOptionExpense contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">25039</OPRX:IndividualStockOptionExpense>
    <OPRX:IndividualStockOptionExpense contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">8346</OPRX:IndividualStockOptionExpense>
    <OPRX:IndividualStockOptionValue contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">40007</OPRX:IndividualStockOptionValue>
    <OPRX:IndividualStockOptionValue contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">35091</OPRX:IndividualStockOptionValue>
    <OPRX:EmployeesStockOptionIssuance contextRef="AsOf2011-05-31" unitRef="Shares" decimals="INF">285000</OPRX:EmployeesStockOptionIssuance>
    <OPRX:EmployeesStockOptionValue contextRef="AsOf2011-05-31" unitRef="USD" decimals="0">320585</OPRX:EmployeesStockOptionValue>
    <OPRX:EmployeesShareBasedCompensationExpense contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">10002</OPRX:EmployeesShareBasedCompensationExpense>
    <OPRX:EmployeesShareBasedCompensationExpense contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">187005</OPRX:EmployeesShareBasedCompensationExpense>
    <OPRX:EmployeesShareBasedCompensationExpense contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">133580</OPRX:EmployeesShareBasedCompensationExpense>
    <OPRX:EmployeesShareBasedCompensationExpense contextRef="From2012-10-01to2012-12-31" unitRef="USD" decimals="0">8335</OPRX:EmployeesShareBasedCompensationExpense>
    <OPRX:EmployeesStockOptionIssuance2 contextRef="From2011-10-01to2011-12-31" unitRef="Shares" decimals="INF">20000</OPRX:EmployeesStockOptionIssuance2>
    <OPRX:EmployeesExercisePricePerShare2 contextRef="From2011-10-01to2011-12-31" unitRef="USDPShares" decimals="INF">1.00</OPRX:EmployeesExercisePricePerShare2>
    <OPRX:EmployeesStockOptionValue2 contextRef="From2011-10-01to2011-12-31" unitRef="USD" decimals="0">19270</OPRX:EmployeesStockOptionValue2>
    <OPRX:MonthlyRentDue contextRef="From2011-12-01to2014-12-01" unitRef="USD" decimals="0">5000</OPRX:MonthlyRentDue>
    <OPRX:MonthlyRentDue contextRef="From2014-12-02to2016-12-01" unitRef="USD" decimals="0">5200</OPRX:MonthlyRentDue>
    <OPRX:TermOfLease contextRef="From2011-12-01to2014-12-01">P3Y</OPRX:TermOfLease>
    <OPRX:TermOfLease contextRef="From2014-12-02to2016-12-01">P2Y</OPRX:TermOfLease>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2013-03-31" unitRef="Shares" decimals="INF">14232496</dei:EntityCommonStockSharesOutstanding>
    <OPRX:SecuritiesRedemptionOptionTextBlock contextRef="From2013-01-01to2013-03-31">&lt;p style="margin: 0pt"&gt;&lt;font style="font-size: 10pt"&gt;On January 10, 2013, the Company entered into a Securities Redemption Option&#13;Agreement with Vicis Capital Master Fund (&amp;#147;Vicis&amp;#148;) that provides the Company with an option to purchase all of the&#13;outstanding shares and derivative securities held by Vicis for total payment of nine million dollars ($9,000,000). The shares&#13;and derivative securities include the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Common Stock,&#13;and warrants to purchase shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock held by Vicis.&#13;The Company&amp;#146;s option expires on December 31, 2013 and may be extinguished if Vicis sells its securities before the Company&#13;exercises its option.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</OPRX:SecuritiesRedemptionOptionTextBlock>
    <OPRX:PaymentToVicisCapitalMasterFund contextRef="AsOf2013-01-10" unitRef="USD" decimals="0">9000000</OPRX:PaymentToVicisCapitalMasterFund>
</xbrli:xbrl>
